Trials / Completed
CompletedNCT04657497
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FOY-305 | Specified Dosage and Duration of Treatment |
| DRUG | Placebo | Specified Dosage and Duration of Treatment |
Timeline
- Start date
- 2020-11-09
- Primary completion
- 2021-03-26
- Completion
- 2021-04-09
- First posted
- 2020-12-08
- Last updated
- 2024-04-05
Locations
25 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04657497. Inclusion in this directory is not an endorsement.